Updates are available Correction dated 2020-01-22
Click to view Correction: https://doi.org/10.1038/s43018-020-0025-7
-
Authors
Abril-Rodriguez, Gabriel
Torrejon, Davis Y.
Liu, Wei
Zaretsky, Jesse M.
Nowicki, Theodore S.
Tsoi, Jennifer
Puig-Saus, Cristina
Baselga-Carretero, Ignacio
Medina, Egmidio
Quist, Michael J.
Garcia, Alejandro J.
Senapedis, William
Baloglu, Erkan
Kalbasi, Anusha http://orcid.org/0000-0001-8692-1457
Cheung-Lau, Gardenia
Berent-Maoz, Beata
Comin-Anduix, Begoña
Hu-Lieskovan, Siwen
Wang, Cun-Yu
Grasso, Catherine S.
Ribas, Antoni http://orcid.org/0000-0003-3669-8458
- License Information
-
More Information
Article History
Received: 26 August 2019
Accepted: 18 October 2019
First Online: 9 December 2019
Change Date: 22 January 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-020-0025-7
Competing interests
: G.A.-R. has received honoraria for consulting with Arcus Biosciences. W.S. and E.B. were employees of Karyopharm Therapeutics when this study was conducted. A.R. has received honoraria for consulting with Amgen, Bristol-Myers Squibb, Chugai, Genentech, Merck, Novartis, Roche and Sanofi, is or has been a member of the scientific advisory board, and holds stock in Advaxis, Arcus Biosciences, Bioncotech Therapeutics, Compugen, CytomX, Five Prime, FLX Bio, ImaginAb, IsoPlexis, Gilead Kite, Lutris Pharma, Merus, PACT Pharma, Rgenix and Tango Therapeutics. G.A.-R., D.Y.T., C.S.G. and A.R. are inventors in a patent application covering the use of PAK4 inhibitors for cancer immunotherapy.
